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Zach. Hilta,*, and Meenakshi Upretib,*
aDepartment of Chemical and Materials Engineering, University of Kentucky, Lexington, KY 
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Abstract
Magnetic hyperthermia as a treatment modality is acquiring increased recognition for loco-
regional therapy of primary and metastatic lung malignancies by pulmonary delivery of magnetic 
nanoparticles (MNP). The unique characteristic of magnetic nanoparticles to induce localized 
hyperthermia in the presence of an alternating magnetic field (AMF) allows for preferential killing 
of cells at the tumor site. In this study we demonstrate the effect of hyperthermia induced by low 
and high dose of MNP under the influence of an AMF using 3D tumor tissue analogs (TTA) 
representing the micrometastatic, perfusion independent stage of triple negative breast cancer 
(TNBC) that infiltrates the lungs. While application of inhalable magnetic nanocomposite 
microparticles (MnMs) to the micrometastatic TNBC model comprised of TTA generated from 
cancer and stromal cells, showed no measureable adverse effects in the absence of AMF-exposure, 
magnetic hyperthermia generated under the influence of an AMF in TTA incubated in a high 
concentration of MNP (1 mg/ mL) caused significant increase in cellular death/ damage with 
mechanical disintegration and release of cell debris indicating the potential of these inhalable 
composites as a promising approach for thermal treatment of diseased lungs. The novelty and 
significance of this study lies in the development of methods to evaluate in vitro the application of 
inhalable composites containing MNPs in thermal therapy using a physiologically relevant 
metastatic TNBC model representative of the microenvironmental characteristics in secondary 
lung malignancies.
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Graphical Abstract
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1. Introduction
Breast cancer is the second leading cause of death in women, surpassed only by lung cancer, 
where one in every eight women that is diagnosed develops the invasive form of this 
dreadful malignancy [1]. Triple negative breast cancer (TNBC) is an aggressive subtype of 
breast cancer wherein the tumor cells do not express the routinely targeted receptors for 
estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) [2] and 
therefore has limited treatment options. Accounting for approximately 20% of all breast 
cancers, TNBC has a disproportionately high rate of metastasis [3]. Additionally, patients 
with distant metastatic disease have a significantly shorter survival time relative to the other 
breast cancer subtypes [4]. The most common ectopic sites for TNBC to metastasize are the 
lungs, the liver, bones and the brain [5] with a higher propensity of metastasis to the lungs 
[3, 6]. Currently there is an unmet and compelling need for novel approaches to treat 
patients with metastatic TNBC.
Pulmonary delivery presents a promising approach for local treatment of both primary and 
secondary lung cancers by facilitating increased drug concentration at the malignant site and 
reduced systemic side effects [7–9]. Clinical trials with stage IV lung cancer patients have 
shown a statistically significant increase in median survival time when carboplatin was 
administered via inhalation combined with injection as opposed to injection only [10]. These 
results suggest that pulmonary delivery has the potential to complement traditional 
approaches for patients with metastatic disease in the lungs. Current initiatives employing 
the delivery of magnetic nanoparticles to the lung is gathering pace for developing novel 
therapeutic approaches that involve thermal sensitization and/or ablation at the malignant/ 
metastatic site [11, 12]. Treatment of recurrent TNBC that metastasizes primarily to the 
lungs aims to improve the quality of life and overall survival. Conventional treatment 
options are however, not defined and systemically administered, therefore result in increased 
overall toxicity. Remote actuation of inhalable magnetic nanoparticles to induce magnetic 
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hyperthermia at the 4 metastatic lesions of TNBC in the lungs is an attractive concept for 
management of the malignancy in advanced stages with reduced systemic toxicity.
The biocompatibility and magnetic properties of iron oxide magnetic nanoparticles (MNP) 
categorizes them in a unique class of materials that have found increasing use in a variety of 
commercialized biomedical applications [13, 14]. The ability of magnetic nanoparticles 
(MNP) and nanocomposites (MnM) to be actuated remotely under the influence of an 
alternating magnetic field (AMF) has sparked interest in their use for thermal sensitization 
of cancer cells/ tumors to maximize therapeutic outcomes [15–17]. In the presence of an 
AMF, iron oxide magnetic nanoparticles generate heat through Brownian and Néel 
relaxation [18]. The regional hyperthermia so generated is utilized to actuate the onset of 
therapy or as a form of therapy itself [19–23]. For cancer patients, researchers have been 
interested in the potential advantages of thermal therapy both in isolation and in combination 
with anti-cancer agents but the translation to clinical settings of such therapies has been 
limited [24–28], owing in part due to the inability of existing tumor models to accurately 
simulate the biological processes and therapeutic response that occur in patients with 
primary and secondary lung cancer
3D co-culture of different cell types that exist in the tumor and its microenvironment provide 
a more physiologically relevant representation of in vivo tissue morphology and function. 
Inclusion of such in vitro tumor models embracing characteristics of the tumor 
microenvironment for understanding and advancing the parameters for thermoablative 
therapy will provide more effective treatment options. To this end, our laboratory has 
developed a 3D co-culture system that incorporates tumor cells, endothelial cells and 
fibroblasts as color-coded murine tumor tissue analogs (TTA) to better recapitulate the 
micrometastatic perfusion independent TNBC tumor biology in vitro [29]. The 3D 
spheroidal co-culture of neoplastic tumor cells with the non-neoplastic stromal components 
facilitates the formation of a natural extracellular matrix (ECM) allowing for a more 
accurate recreation of the tumor microenvironment that is often overlooked in in vitro 
assays.
In the current study, we have devised cost-effective and reproducible in vitro methods using 
color coded TNBC micrometastatic TTA developed in the laboratory to investigate the 
potential of inhalable formulations of MNP for secondary lung cancer patients with 
metastatic TNBC. The murine TNBC micrometastatic TTA are comprised of mCherry 
fluorescent protein expressing 4T1 tumor cells, the GFP expressing C166 endothelial cells 
and murine embryonic fibroblasts (MEF) that are grown in in hanging drops of medium 
without the use of any artificial matrices to a size of ~600 µm [30]. The murine 4T1 breast 
carcinoma cell line does not express the ER, PR and HER2 receptors and is therefore 
representative of the TNBC phenotype [31]. The spray dried MNP are formulated into 
inhalable magnetic nanocomposites (MnM) [32] before incubating with the TTA. Remote 
controlled thermal therapy on TTA is accomplished using a custom AMF and the treated 
tissues are analyzed both quantitatively and qualitatively.
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2. Material and methods
2.1. Cell Lines and Culture
4T1-mCherry is a red fluorescent protein-expressing murine metastatic mammary carcinoma 
cell line that closely mimics the triple negative subtype of human breast cancer [33]; was a 
kind gift from Dr. D. D. Schlaepfer (University of California, San Diego, CA). 2H11, murine 
tumor endothelial cell line [34], and C166-GFP, a murine green fluorescent protein-
expressing endothelial cell line, were purchased from ATCC (Manassas, VA). Murine 
embryonic fibroblasts (MEF) were a kind gift from Dr. V. Rangnekar (University of 
Kentucky, Lexington, KY). The cell lines were routinely cultured in high glucose DMEM 
containing 10% (v/v) fetal bovine serum and 100 IU/mL penicillin, 100 IU/mL streptomycin 
at 37 °C, 5% CO2, and 95%.
2.2. Chemicals and Reagents
Iron(II) chloride tetrahydrate (FeCl2·4H2O), iron(III) chloride hexahydrate (FeCl3·6H2O), 
and d-mannitol were purchased from Sigma–Aldrich (St. Louis, MO). Ammonium 
hydroxide (NH4OH) was obtained from EMD chemicals (Gibbstown, NJ). Chloroform, 
anhydrous methanol, and high performance liquid chromatography-grade methanol were 
purchased from Fisher Scientific (Pittsburgh, PA). Ultrahigh-purity nitrogen gas was 
purchased from Scott-Gross (Lexington, KY).
2.3. Formulation and Characterization of MnM and MNP
Detailed discussion on formulation and characterization of the MnM and MNP is as 
described in our previous publication[12]. Briefly, magnetic nanocomposite microparticles 
(MnMs) were formulated by spray drying of iron oxide MNPs and D-mannitol. The 
physicochemical properties of these MnMs were evaluated and the in vitro aerosol 
dispersion performance of the dry powders was measured by the Next Generation 
Impactor®. For all powders, the mass median aerosol diameter (MMAD) was <5 µm and 
deposition patterns revealed that MnMs could deposit throughout the lungs. Heating studies 
with a custom AMF showed that MNPs retain excellent thermal properties after spray drying 
into composite dry powders, with specific absorption ratios (SAR) > 200 W/g.
2.4. Formation of TNBC micrometastasic TTA
4T1-mcherry tumor cells, C166-GFP endothelial cells and murine embryonic fibroblasts 
(MEF) were used to generated 3D BCM tumor tissue analogs in “hanging drops” of media 
(Dulbecco modified Eagle medium with 10% fetal bovine serum and antibiotic mix) as 
previously described [29, 30]. Briefly, the single a cell suspension of 4T1-mcherry cells, 
C166-GFP cells and MEF cells in equal proportion (3000 cells/20µL) was dispensed on the 
inside of the lid of each well of a 48-well cell culture plate (Greiner Cellstar, Kaysville, UT). 
The growth of tumor tissue analogs was monitored over time until day 10 in a hanging drop 
of medium, following which they were subject to MNP (Magnetic nanoparticle) or AMF 
(Alternating magnetic field) treatment. The tumor tissue analogs were transferred to 
optically clear repellent plates (Greiner Cellstar, Kaysville, UT) or placed on Millicell 
culture inserts (Millipore, Billerica, MA) for MNP and AMF treatment respectively. 
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Subsequent imaging of TTA and analysis of the treatment response was performed in the 
repellent plates (Griener, Cellstar, Kaysville, UT).
2.5. MNP-treatment of TNBC micrometastatic TTA
The MNP were dispersed in Dulbecco modified Eagle medium with 10% fetal bovine serum 
and antibiotic mix at concentrations of 1.0 mg/mL and 0.1 mg/mL. These two treatment 
groups will be referred to as high dose (HD) and low dose (LD), respectively. Five 
microemtastatic TTA in each well of a 96-well plate were incubated in 50 ml of the 0.1 
mg/mL (LD) and 1.0 mg/mL (HD) MNP dispersion for 24 hours at 37°C in a humidified 
environment supplemented with 5% CO2. For the controls fresh medium was added in each 
well. 20 micrometastatic TTA were analyzed in each treatment group as summarized in 
Table. 1. Subsequently the TTA were rinsed three times with medium [Dulbecco modified 
Eagle medium with 10% fetal bovine serum and antibiotic mix] and placed on a cell culture 
insert (Millipore, Billerica, MA) within a 35 mm petri dish (Greiner Cellstar, Kaysville, 
UT). 2ml of medium was added the dish to ensure sufficient supply of nutrients and a solid-
air interface for the TTA during hyperthermia treatments.
2.6. Remotely actuated hyperthermia using a custom alternating magnetic field (AMF)
For hyperthermia experiments each 35 mm petri dish with the TNBC micrometastatic TTA 
lodged on the cell culture insert, was placed directly above the coil of a custom Taylor 
Winfield® Alternating Magnetic Field (AMF) Source (Youngstown, OH). The AMF was run 
at a field strength of 55 kA/m and a frequency of 300 kHz. The treatment groups were 
exposed to the AMF field for 1 hour. During the experiments a custom built Styrofoam 
casing was used to enclose the coil and petri dish and a hot air supply was used to maintain 
the temperature of the surroundings to approximately 37°C. A Luxtron fiber Optic 
Thermometer (LumaSense Technologies, Santa Clara, CA) was used to measure the 
temperature of the surroundings throughout the experiments. The hot air supply was 
adjusted manually in order to maintain the surrounding temperature to 37°C. After AMF-
exposure, each treatment group was allowed to incubate for 4 hours at 37°C in a humidified 
environment supplemented with 5% CO2. The BCM tumor tissue analogs were then fixed in 
4% formaldehyde for 24hrs. Table 1 summarizes the treatment groups in this study and the 
corresponding naming convention used here.
2.7. Fluorescent imaging on micrometastatic tumor tissue analogs
After being subject to remotely actuated hyperthermia the BCM tumor tissue analogs (n=5/ 
treatment group) were incubated for 72 hours at 37°C in a humidified environment 
supplemented with 5% CO2 and imaged with a FV1000 laser scanning confocal microscope. 
Images were processed using FV10-ASW 1.7 viewer software. Images were analyzed using 
Olympus image analysis software and ImageJ 1.47v (NIH, Bethesda, USA) as 8-bit 
monochromatic image files. Accumulation of Sytox blue staining, mCherry- and GFP-
expressing cells was imaged using argon lasers at 406 nm, 532 and 453 nm, respectively. 
Bright field images were captured to estimate the size of the micrometastatic TTA.
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2.8. Quantification of cell death using Sytox Blue
In order to quantify the amount of cell death five BCM tumor tissue analogs per treatment 
group were stained with Sytox Blue (n=5/group). The SYTOX blue stain (Molecular Probes, 
Inc, Eugene, OR) is a high-affinity nucleic acid stain that easily penetrates cells with 
compromised plasma membranes and can be excited with argon 406 lasers, making it a 
useful indicator of dead cells within a population.
2.9 Prussian blue staining and imaging of iron uptake
The amount of iron present in TNBC micrometastatic TTA was evaluated using a Prussian 
Blue stain for iron content. TTA were harvested and processed through sucrose gradient and 
then snap frozen in O.C.T, Tissue-Tek, Miles USA, Inc. (Elkhart, IN). Five micrometer 
cryostat sections were obtained with the help of a Leica CM1950 cryotome and transferred 
on to Superfrost™ Plus slides (Fischer Scientific; Boston, MA) for detection of iron-oxide 
particles using Prussian blue staining. Slides were incubated in freshly prepared 10% 
aqueous solution of potassium ferrocyanide and hydrochloric acid for 20 minutes, washed 
three times with distilled water and counterstained with nuclear red for 5 minutes. After 
rinsing the slides, sections were dehydrated through grades of alcohol and then cleared with 
xylene and permanently mounted with permount media (Sigma) and coverslip. Light 
microscopic images were obtained at 10× and 20× magnification using Olympus light 
microscope (Olympus America Inc., Melville, NY).
2.10. Transmission electron microscopy (TEM) for intra-structural changes in TTA post-
treatment
Transmission electron microscopy (TEM) was carried out on TM analogs (n=5) in order to 
qualitatively observe MNP uptake and cellular characteristics after AMF treatment. 
Immediately following 1 hour of AMF exposure the TTA were placed in an incubator for 4 
hours at 37°C in a humidified environment supplemented with 5% CO2. Subsequently, TTA 
were transferred to a 20 mL glass vial and washed with 0.1 M Sorenson’s Phosphate Buffer 
(SPB) to remove media before fixing. The buffer was removed and a 3.5% glutaraldehyde 
solution in 0.1 M SPB was added to the vial and allowed to sit for 45 min at approximately 
4°C. Subsequently, the fixate was removed and the TTA were washed three times for 5 
minutes in 0.1 M SPB supplemented with 5% sucrose. After this, the SBS was removed and 
a 1% osmium tetroxide solution in 0.1 M SPB was added to the vial containing the TTA and 
allowed to sit for 45 mins at 4°C. The osmium tetroxide solution was removed and TTA 
were washed with 0.1 M SPB and dehydrated by subsequent ethanol washes at 50-, 70-, 80-, 
90-, and 100% (twice) for 10 mins each. After the second wash with 100% ethanol the TTA 
were washed with propylene oxide twice for 20 mins each. The propylene oxide was then 
removed and the TTA were allowed to sit overnight under a mild heating lamp in a 1:1 
mixture of propylene oxide and an epoxy resin. The next day, the propylene oxide and epoxy 
resin mixture was removed and the cells were washed with just the epoxy resin twice for an 
hour each time. After the second wash was removed the TTA were transferred to a 
centrifuge tube for sectioning, epoxy resin was added and the samples were allowed to 
polymerize for 48 hours at 60°C. After polymerization, the pellets were sliced into 70–90 
µm sections with a Reichert-Jung Ultracut E microtome and stained with a combination of 
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uranyl acetate, (saturated solution in 70% ethanol) for 5 minutes, and lead citrate, for 2 
minutes. The specimens were observed using a Philips Tecnai Biotwin 12, manufactured by 
FEI.
2.11. Image processing and analysis
Images of cell vacuolization and nanoparticle aggregation were manually colored and 
processed using Adobe Photoshop CS6 (Adobe Systems Inc., San Jose, CA). Colored 
regions were extracted from the original image with the use of Adobe Photoshop CS6. Area 
analysis of the colored regions was conducted with the use of ImageJ, v1.47 (National 
Institutes of Health, Bethesda, MD).
2.12. Statistical Analysis
Data are expressed as mean ± 1 SD of at least three different experiments. Statistical 
significance of difference in means was performed using parametric two sample t test with 
unequal variance (α=0.05; GraphPad Prism).
3. Results and Discussion
3.1. Increasing exposure to iron oxide MNP masks the fluorescence intensity of color 
coded cell types in TTA
The effect of MNPs, released from the inhalable dry composites, on the micrometastatic 
TTA (n=5) was examined 5 days post MNP-exposure with fluorescent confocal and 
differential contrast interference (DIC) microscopy for three different MNP doses namely 
control, LD (0.1 mg/mL), and HD (1 mg/mL). The increasing concentration of MNP 
exposure masked the fluorescence intensity of different cell types comprised in the TTA 
upon incubation with increasing MNP concentration (Fig. 1). The incubation with increasing 
concentrations of MNP is expected to cause higher levels of MNP deposition on TTA 
resulting in dark areas where the nanoparticles diffract light and obscure fluorescence of 
color coded cell types in the multicellular TTA. This is a common issue with in vitro 
fluorescent assays using MNPs and must be taken in consideration when analyzing the data.
In addition to illustrating the reproducibility, the data shows no apparent adverse effect on 
the mechanical stability of the TTA upon exposure with MNP alone and confirms the 
multicellular composition evidenced by the presence of all three cell types namely, the MEF 
(colorless), 4T1 (red) and C166 (green) cells in the TTA.
3.2. AMF exposure causes mechanical deterioration in TTA incubated with increasing 
concentration of MNP
The effect of AMF-exposure on TTA with and without incubation with MNP was also 
examined using fluorescent and bright field (DIC) microscopy. TTA from each treatment 
group (n=5) were placed in an AMF for 1 hour (designated +AMF) that were compared with 
their corresponding TTA incubated with the same MNP dose but not placed in AMF 
(designated −AMF). While no difference was observed in the−AMF and +AMF control 
groups that were not incubated with MNP, mechanical deterioration was noticed in the TTA 
incubated with MNP. Increasing mechanical breakdown after AMF exposure was evidenced 
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by occurrence of cellular debris surrounding TTA incubated in higher concentration of MNP 
(Fig. 2). This effect was increasingly pronounced in the HD MNP+AMF treatment group 
wherein large amounts of cellular debris were observed (Fig 2).
3.3. Increased cellular damage and MNP accumulation in TTA exposed to high dose of 
MNP remotely actuated via an AMF
Cellular damage by magnetic hyperthermia from MNP subject to AMF exposure was 
quantified in the in vitro micrometastatic TNBC model using TTA to examine the potential 
of the inhalable composites for treatment of secondary lung malignancies. The extent of 
cellular damage was assessed by quantification of SYTOX® Blue uptake in the TTA from 
each treatment group (n=5). Sytox blue is a fluorescent nuclear counterstain impermeant to 
live cells and a useful indicator of cell death and damage. Fluorescent images captured at 
480 nm revealed higher staining for SYTOX® Blue in TTA incubated in increasing 
concentration of MNP and AMF exposure for 1 hr (Fig. 3A).
The normalized mean integrated fluorescence intensity of the SYTOX® Blue in TTA from 
each treatment group was calculated. The graphical representation of the quantitative data 
(Fig. 3B) showed comparable levels of cell death/damage in all treatment groups without 
AMF exposure (−AMF), but an increase in cell death / damage in both the low and high 
dose MNP treatment groups of TTA that were subject to magnetic hyperthermia induced by 
an AMF for 1 hr (LD MNP +AMF and HD MNP +AMF) (Fig 3B). Furthermore, despite the 
potential reduction in the fluorescent intensity of color coded cell types in the TTA subject 
to treatment with high dose MNP and AMF exposure (HD MNP+AMF) as described in Fig. 
1, a statistically significant increase (p<0.05) in cell death/ damage was observed only in this 
treatment group. Control groups with and without AMF exposure did not show any notable 
increase in SYTOX® Blue intensity.
3.4. Magnetic hyperthermia induced via an AMF increases the MNP uptake in TTA
To investigate the accumulation and agglomeration of the MNPs in the TTA, histological 
sections were cut and stained with Prussian blue for iron content. As evidenced from the 
images there was higher amount of iron in the TTA incubated at a higher dose (HD) of MNP 
(Fig. 4). Interestingly, this increase in iron accumulation with HD MNP treatment was much 
more uniform in the TTA that were subject to AMF exposure for 1 hr. Iron accumulation in 
TTA subject to HD MNP treatment only was restricted to the peripheral TTA layers. Images 
of TTA not treated with MNP (Control) with or with exposure to AMF did not exhibit any 
changes (Fig. 4).
3.5. TEM elucidates varying patterns of iron uptake in TTA exposed to low and high dose of 
MNP with magnetic hyperthermia induced via an AMF
To gain better insights into the MNP-localization and cellular response post AMF exposure, 
the TTA were cast in resin, sectioned, and stained for TEM imaging. Electron micrographs 
acquired from the interior and exterior regions of the TTA incubated in low and high dose of 
MNP with AMF exposure revealed different patterns of iron uptake in the two treatment 
groups (LD MNP +AMF and HD MNP+AMF) (Fig. 5).
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TEM images from the center (interior) of the TTA showed some accumulation of MNP 
within cell vacuoles and comparable uptake in intercellular spaces or vacuoles in the 
periphery (exterior) of the TTA at 5 days’ post treatment with LD+AMF (Fig. 6A). The HD
+AMF treatment of TTA however, displayed the bulk of MNP agglomerates accumulated in 
the interior with marginal acquisition in the exterior of the TTA. Quantitative analysis of 
MNP accumulation further confirms higher accumulation of MNP in the interior of TTA 
upon treatment with higher dose of MNP in comparison to the lower dose of MNP when 
accompanied with magnetic hyperthermia induced using AMF (Fig. 6B & C). The MNPs 
that are released from the composite powders have a core diameter of approximately 10 nm 
and a hydrodynamic diameter of approximately 150 nm [12] during exposure to the TTA; 
however, a large portion of the MNP that accumulate in TTA appear as very large 
agglomerates. A possible explanation could be owing to the deposition of MNP on the 
surface of TTA during the 24 hr incubation period.
3.6 TEM images indicate vacuolization and extracellular deposition in TTA when exposed 
to magnetic hyperthermia induced via remote actuation of MNP by an AMF
Conditions including magnetic hyperthermia that cause cellular stress may induce multiple 
distinct types of tumor cell death, such as: apoptosis, necrosis and autophagy, occurring 
concurrently or successively [35–39]. In addition, heat-generating magnetic nanocubes have 
demonstrated the potential to ‘destructure’ the extracellular matrix in the tumor stroma and 
improve nanoparticle / drug penetration at the tumor site [40]. In this study we are also able 
to observe morphologic features of autophagy such as accumulation of extracellular debris 
and vacuolization in TTA subject to MNP exposure with AMF (Fig. 7) [41].
While the vacuolization (red arrows) was much more prevalent in TTA treated with low dose 
of MNP with AMF (LD MNP+AMF), the nanoparticle agglomerates within cells (Blue 
outline) and extracellular deposition (yellow arrows) was notably higher in TTA exposed to 
high dose MNP and AMF exposure (HD MNP+AMF) (Fig. 7)
Increasing magnification of the electron photomicrographs elucidated upon engulfment of 
small amounts of MNP in TTA treated with LD MNP+AMF (Fig. 8, middle and lower 
panel). This phenomenon of cytoplasmic vacuolization and precipitation of extracellular 
debris indicating autophagy was not observed in TTA that were subject to AMF exposure 
alone (Control+AMF) (Fig. 8, top panel). A quantitative analysis for vacuolization of the 
cytoplasm in TTA post treatment from TEM images further confirmed their formation as a 
consequence of low dose MNP exposure with an AMF (Fig. 9, middle panel). While large 
agglomerates of MNP were formed in TTA upon exposure to high dose of MNP subject to 
an AMF (Fig. 9, lower panel), no significant vacuolization was observed upon quantitation 
(Fig. 9B, C). The phenomenon of cytoplasmic vacuolization was also not observed in 
treatment groups not exposed to an AMF and Control groups that were not incubated with 
MNP.
Efforts are underway to standardize more powerful techniques such as second harmonic 
generation microscopy to analyze alterations in extracellular matrix proteins (collagen), 
confocal and immunohistochemistry of TTA microarrays to delineate the role of different 
cell types contributing to the tumor response in vivo.
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4. Conclusions
AMF-assisted forced oscillations of magnetic nanoparticles (MNP) The effectiveness of 
magnetic hyperthermia has been demonstrated using aerosolized nanocomposites as 
inhalable super paramagnetic iron oxide (SPIO) nanoparticles in an orthotopic lung cancer 
mouse model where a significant reduction in micrometastatic-NSCLC tumor growth was 
observed with exposure to an AMF [42]. Others have reported the ability to target liquid 
aerosols containing MNPs to specific regions within the lungs of mice by application of a 
stationary magnetic field [43, 44]. Such findings illustrate the potential of these MNP-
containing inhalable aerosols for treatment of patients with primary or metastatic lung 
cancer where surgery is not recommended [45]. Preclinical animal investigations of inhaled 
therapeutics in lung malignancies however, depend on complicated intratracheal and 
intranasal routes monitored in appropriate animal models requiring a significantly large 
sample size. Therefore, to decipher the intracellular events triggered by magnetic 
hyperthermia and standardize the optimal dose by titration of MNP concentration with the 
duration of AMF exposure, it is imperative to develop in vitro tumor models that are able to 
recapitulate the microenvironmental aspects of the lung malignancy and allow high 
throughput screening in a cost-effective and reproducible manner. Controlled experimental 
manipulations in vitro settings present an extremely useful predictive tool for optimization 
of dosing schedules before translation of data to animals and clinical trials [46]. The TNBC 
micrometastasic tumor tissue analogs (TTA) developed in our laboratory have demonstrated 
a consistent size, tissue-like morphology, natural extracellular matrix and presence of 
markers representative of the tumor tissue [30], thereby highlighting their potential as 
advanced in vitro models for understanding treatment response in secondary lung 
malignancies. The experimental design for induction of magnetic hyperthermia in the 
present study with the TTA laid on transwell inserts mounted on petri dishes containing 
media recreated the air-liquid interface as observed in primary lung cancer and ectopic lung 
metastasis such as TNBC. Application of inhalable magnetic nanocomposite microparticles 
(MnM) to the micrometastatic TNBC model (TTA) showed no measureable adverse effects 
in the absence of AMF-exposure. However, hyperthermia induced via an alternating 
magnetic field in TTA subjected to a high concentration of MNP (1 mg/ mL) showed 
statistically significant increase in cellular death with higher accumulation of MNP, 
indicating the potential of these inhalable composites for future development of thermal 
therapy. Additional morphological changes evidenced as a consequence of hyperthermia 
induced by remote actuation of MNP under an AMF in the TTA, were mechanical 
deterioration that was demonstrated by confocal microscopy and vacuolization with 
extracellular deposition observed in the TEM images of the TTA. While we are still in the 
process of developing novel strategies to investigate the multiple effects of magnetic 
hyperthermia such as apoptosis, necrosis and autophagy in conjunction with the 
standardization of MNP distribution in our 3D micrometastatic tumor model, the TTA used 
in this study provide a physiologically relevant in vitro model of secondary lung 
malignancies from metastatic TNBC and our findings suggest the potential of inhalable 
composites containing MNP for inducing locoregional hyperthermia in primary and 
secondary lung cancer. While AMF-assisted thermal therapy has received global attention, 
recent reports suggest that forced oscillation of MNP via low power and low frequency AMF 
Stocke et al. Page 10
Biomaterials. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(35 kHz) result in direct mechanical damage of cancer cells without causing any thermal 
injury [47–49]. We expect the 3D microemetastatic model as an ideal test-bed or platform 
for comparison of the direct effects of MNP oscillations via low frequency AMF with the 
indirect thermal effects induced by high frequency AMF and development of biomedical 
applications for MNP in cancer therapy.
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Figure 1. MNP exposure masks the fluorescence of color coded cell types in the TTA
Confocal Microscopy and DIC images of TTA without and with 0.1 mg/mL, low (LD) and 1 
mg/mL, high (HD) dose of MNP exposure. The treatment groups are arranged in columns 
with increasing MNP dose from left to right. Each treatment group has 3 replicates. Each 
panel consists of the following 4 images: GFP: (green fluorescent protein-expressing C166 
endothelial cells, top left), RFP: (red fluorescent protein-expressing 4T1 murine mammary 
carcinoma cells, top right), DIC: (differential interference contrast image, bottom left), and 
OV: (overlay of the images, bottom right). Images were capture day 5 post treatment.
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Figure 2. MNP exposure combined with Magnetic hyperthermia induced by AMF exposure 
causes release of cellular debris from TTA
Comparison of TTA with- (+AMF; bottom row) and without (−AMF; top row) application 
of AMF for 1-hour. The treatment groups are arranged in columns with increasing MNP 
dose from left to right. Each panel consists of the following 4 representative confocal 
images: green fluorescent (GFP-expressing C166 endothelial cells, top left), red fluorescent 
(RFP-expressing 4T1 murine mammary carcinoma cells, top right), DIC (bottom left), and 
overlay (bottom right). Images were captured at day 5 post MNP exposure.
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Figure 3. Increased cell damage in TTA resulting from MNP exposure and AMF induced 
magnetic hyperthermia
(A) Representative images of cell damage upon low dose (0.1 mg/mL) [LD] and high dose 
(1 mg/mL) [HD] treatment with and without AMF exposure as indicated by Sytox blue 
staining. (B) Toxicity of the MNP with and without magnetic hyperthermia induced by AMF 
exposure for 1 hr. was evaluated by quantification of dead cell count measured as the mean 
integrated density of blue signal of the Sytox blue staining from fluorescent images using an 
ImageJ software and graphically represented. (N= 5 TTA/group, *p < 0.05, for TTA exposed 
to HD MNP with AMF compared to all other treatment groups).
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Figure 4. Higher accumulation of MNP in TTA with MNP exposure combined with AMF 
induced magnetic hyperthermia
Representative images of Prussian blue staining of microemetastatic TTA counterstained 
with nuclear fast red at 20× that were treated with low dose (0.1 mg/mL) [LD MNP] and 
high dose (1 mg/mL) [HD MNP] of MNP with and without exposure to magnetic 
hyperthermia induced by AMF for 1 hr. The untreated TTA [Control] served as control.
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Figure 5. Representative TEM images demonstrating accumulation of MNP in the interior and 
exterior regions of the TTA 5 days post magnetic hyperthermia induced by remote actuation of 
the MNP upon low dose (LD, 0.1 mg/mL) and high dose (,HD 1.0 mg/mL) incubation with the 
TTA
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Figure 6. Quantitative analysis of MNP accumulation in the interior and exterior regions of TTA 
upon treatment with low and high dose of MNP with magnetic hyperthermia induced by AMF
(A) Representative TEM images from the interior and exterior regions of the TTA post 
treatment as indicated in the figure that were manually colored for nanoparticle aggregation 
and processed using Adobe Photoshop CS6. The area of the extracted colored region was 
analyzed and quantitated using the ImageJ software. The data obtained was graphically 
represented as MNP area (B) and MNP percentage (C). N= 3 TTA/group, *p < 0.05, for 
TTA interior exposed to HD MNP with AMF compared to TTA interior with LD+AMF and 
TTA exterior with HD+AMF treatment.
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Figure 7. Increased nanoparticle accumulation or massive vacuolization and deposition of 
extracellular material upon MNP exposure with magnetic hyperthermia in TTA
(A) Representative TEM images from the center of the TTA showing nanoparticle 
accumulation (Blue outline), vacuolization (red arrows) and extracellular deposition (yellow 
arrows) when subjected to the following treatments: (i) Control–AMF; (ii) LD–AMF; (iii) 
HD−AMF; (iv) Control+AMF; (v) LD+AMF; (vi) HD+AMF. Scale bar: 10 µm.
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Figure 8. Representative TEM images from the center of the TTA with increasing magnification 
revealing aggregation of MNPs in the either in vacuoles and cells exposed to magnetic 
hyperthermia induced via remote actuation of low and high dose of MNP exposure using an 
AMF for 1 hr respectively
TTA subject to AMF only [Control] served as control. Scale bar: 5, 2 and 1 µm.
Stocke et al. Page 21
Biomaterials. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 9. Quantitative analysis of vacuolization of the cytoplasm in TTA post treatment
(A) Representative TEM images that were manually colored for vacuolization and processed 
using Adobe Photoshop CS6. The area of the extracted colored region was analyzed and 
quantitated using the ImageJ software. The data obtained was graphically represented as 
vacuolization area (B) and vacuolization percentage (C). N= 3 TTA/group, *p < 0.05, for 
TTA exposed to low dose MNP with AMF compared to high dose and control with AMF.
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Table 1
BCM tumor tissue analogs (5 BCM microtissues/petridish with replicates each) were randomized into six 
treatment groups as summarized.
System [MNP]
(mg/mL)
MNP exposure
time (hours)
AMF exposure
time (hours)
Control - 24 0
LD MNP 0.1 24 0
HD MNP 1.0 24 0
Control + AMF - 24 1
LD + AMF 0.1 24 1
HD + AMF 1.0 24 1
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